H.C. Wainwright lowered the firm’s price target on Kyverna Therapeutics (KYTX) to $4 from $6 and keeps a Neutral rating on the shares following the Q4 report.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYTX:
- Kyverna Therapeutics price target lowered to $20 from $40 at Morgan Stanley
- Kyverna Therapeutics: Strategic Advancements and Robust Financial Health Underpin Buy Rating
- Kyverna Therapeutics price target lowered to $12 from $13 at UBS
- Kyverna Therapeutics Advances CAR T-Cell Therapy Trials
- Kyverna Therapeutics files $250M mixed securities shelf